Cancers with as few as 1% of cells positive for Estrogen Receptor (ER) or Progesterone Receptor (PR) expression via ImmunoHistoChemistry (IHC) staining are considered ER or PR-positive, respectively [11]. Here, ESR1 is linked to cancer.